Key result
Prompt alteplase and endovascular therapy reduce neurologic disability in acute ischemic stroke.
Why the study?
Stroke is a major cause of mortality and morbidity, and thrombolysis has driven major changes in acute ischemic stroke management.
Answers are grounded in this paper and cite their sources.
Narrative review demonstrates the efficacy of early intravenous alteplase in acute ischemic stroke, highlighting recent advances in thrombolytic management.
Stroke is a major cause of mortality and morbidity, and thrombolysis has served as a catalyst for major changes in the management of acute ischaemic stroke. Intravenous alteplase (recombinant tissue plasminogen activator) is the only approved thrombolytic agent at present indicated for acute ischaemic stroke. Recombinant tissue plasminogen activator (rt-PA) therapy is effective in reducing early and long-term neurologic disabilities if it is started quickly. This article summarizes the recent advances in thrombolysis for acute ischaemic stroke.
No takes yet. Share an insight, caveat, or question.
Asija et al. (2022) conducted a review in Acute ischemic stroke. Acute stroke management (intravenous thrombolysis and endovascular treatment) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: